CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment: a pilot study

Alessandro Agnoli, Giovanni Fabbrini, Mario Fioravanti, Nicola Martucci

Research output: Contribution to journalArticle

Abstract

Ten patients diagnosed as affected by primary degenerative dementia of the Alzheimer type, with a mild to moderate cognitive and behavioral impairment, were studied in a double blind design when taking for 60 days 5 mg twice a day of L-deprenyl or placebp. Cognitive functions and cerebral blood flow were assessed at the beginning and at the end of treatment by a wide array of memory, attention, and language efficiency measures and by SPECT-99TcHMPAO procedure. Reduced CBF on the parietal lobes was demonstrated in the patients at baseline together with a reduction of memory and cognitive efficiency. At the end of the treatment patients who received L-deprenyl showed an improvement in cognitive efficiency and no changes in CBF, while patients treated with placebo showed a worsening of cognitive efficiency and further reduction of parietal lobe CBF.

Original languageEnglish
Pages (from-to)31-35
Number of pages5
JournalEuropean Neuropsychopharmacology
Volume2
Issue number1
DOIs
Publication statusPublished - 1992

Keywords

  • Dementia
  • Monoamine oxidase inhibitors
  • single photon emission computed
  • Tomography

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)

Fingerprint Dive into the research topics of 'CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment: a pilot study'. Together they form a unique fingerprint.

  • Cite this